---
title: "Treatment of ovarian cancer"
date: "2023-02-08"
enableToc: false
---

> [!info] 
> 
> ðŸŒ±ä¾†è‡ª: [[ovarian cancer]]

# Treatment of ovarian cancer
â€¢ Cytoreductive surgery: survival benefit even for stage IV and relapsed disease (Gynecol Oncol 2013;130:493; NEJM 2021;385:2123). Consider neoadj. chemo to â†‘ likelihood of maximal cytoreduction at surgery and reduce surgical morbidity.
â€¢ Chemo: 1st line (neoadj., adj., adv.): carboplatin+paclitaxel (CP). [[parpi.md|PARPi]] maintenance (olaparib, niraparib, rucaparib; esp if homologous recombination deficient [eg, BRCA1/2]) or bevacizumab maintenance if homologous recombination proficient.
â€¢ Recurrence at >6 mos = platinum sensitive â†’ Rx w/ platinum doublet. If <6 mos = platinum resistant â†’ single agent chemo (eg, liposomal doxorubicin, gemcitabine) Â± bevacizumab.
